Single-tablet HIV regimen hits safety, efficacy targets

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Once-daily single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide effectively suppresses virological rebound in treatment-experienced HIV-1 infected (TE-HIV) adults.
  • Regimen is noninferior to boosted protease inhibitor (BPI) combined emtricitabi...